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Identity 
Other names: REIC, RIG 






DKK3 gene is 46367 bp long, containing nine exons 
that span over 50 kbp of genomic DNA (Kobayashi et 
al., 2002).  
 
 
DKK3 gene location at chromosome 11p15.2, and its annotated transcripts. Exons are indicated as boxes, Blue boxes present 
untranscripted region (UTR). The start codon (ATG) in exon 2, and stop codon (TAG) in exon 8 are indicated as arrows. 
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All the DKK3 gene transcripts encode a 350 aa, 38.3 kDa glycoprotein (NM_015881→NP_056965, NM_013253→NP_037385, and 
NM_001018057→NP_001018067, respectively). DKK3 protein contains N-terminal signal peptide, two cysteine rich domains (i.e. DKK-
type Cys-1 and DKK-type Cys-2). DKK-type Cys-1 is located within the DKK_N (Dickkopf N-terminal cysteine rich region, pfam04706) 
region. DKK-type Cys-2 include prokineticin region (pfam06607, white dashed lines). Two coiled-coil regions are present in N-terminal 
side and C-terminal side. Putative N-glycosylation sites are indicated. 
 
There are two exons in exon 1, which are alternatively 
used in two different transcripts. Totally, three 
transcript variants are known. 
Transcription 
DKK3 gene is transcribed into three different isoforms 
(NM_015881, 2650 bp, NM_013253, 2635 bp, and 
NM_001018057, 2587 bp). Two of them result from 
alternative use of first exon (i.e. exon 1a and exon 1b, 
although they are both non-coding). One more variant 
lacks exon 1. All the variants share exons 2 to 8, and





DKK3 protein possesses several defined regions, which 
may confer multiple functions to the protein. Amino 
acid (aa) 1-21 is a signal peptide (SP) that characte izes 
this protein as a secreted protein. Four putative N-
glycosylated sites and O-glycosylated at one site region 
(aa 26-46) suggest that the protein may undergo 
posttranslational modification before its secretion. 
Two cysteine-rich domains are conserved over species. 
N-terminal one is DKK_N (formerly called Cys-1) and 
C-terminal one is called Colipase fold (formerly called 
Cys-2). Both two domains contain 10 cysteine residues 
and are separated by a 12 aa linker region. Colipase 
fold features lipid hydrolysis and may contribute to 
lipid binding (interact with cell surface LRP5/LRP6, 
for instance). Colipase fold is solved to form interactive 
surface with finger-like structure. The presence of 
coiled-coil domain suggests possible protein-protein 
interaction. All these structural features facilitate 
Wnt/DKK interactions (as will be apparent below). 
Moreover, DKK3 possesses potential proteolytic 
cleavage sites by furin-type proteases, suggesting that 
the protein is subject to posttranslational processing. 
Expression 
Human DKK3 DNA/RNA expression is widely 
observed in human normal tissues. Northern blotting 
analyses reveal that DKK3 mRNA is expressed in 
brain, heart, lung, liver, pancreas, spleen, kidney, small 
intestine, colon, skeletal muscle and placenta. Amongst 
them, DKK3 expression is particularly high in heart 
and brain. 
Reflecting the alias of this gene, RIG (Regulated in 
glioma) or REIC (Reduced expression in cancer), 
DKK3 mRNA and protein expression is deregulated in 
a wide range of tumors, including glioma, gastric 
carcinoma, colorectal carcinoma, hepatocellular 
carcinoma, pancreatic cancer, leukemia, renal cell 
carcinoma, bladder carcinoma, prostate cancer, 
testicular carcinoma, ovarian carcinoma, cervical 
cancer, breast cancers, non-small cell lung cancer, 
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mesothelioma and skin cancers. This downregulation in 
mRNA expression is caused by promoter 
hypermethylation.  
Thus, DKK3 is thought to be a potential tumor 
suppressor, and is focussed as a therapeutic target. 
However, in DKK3 protein expression level, some 
reports show that DKK3 protein expression is up-
regulated, suggesting cancer specific expression pattern 
and potential alternative role in cancer invasion. 
Localisation 
DKK3 protein is an extracellular secreted protein. Its 
intracellular localization is observed in cytoplasm, 
organelle and endoplasmic reticulum. 
Function 
DKK is firstly identified in Xenopus embryogenesis 
(Glinka et al., 1998), and named after its role as head 
inducer, Dickkopf (dick=thick, kopf=head). DKK binds 
to the Wnt co-receptor, lipoprotein receptor-related 
protein5/6 class (LRP5/6), and exert antagonistic 
function for Wnt induced beta-catenin stabilization 
(Fedi et al., 1999; He et al., 2004). DKKs play an 
important role in vertebrate antero-posterior axial 
patterning, limb formation,  
 
eye formation and bone formation (Niehrs, 2006). 
The Wnt signaling inhibitory ability differs between the 
DKK members; DKK1 and DKK4 can inhibit 
Wnt/beta-catenin pathway, and DKK2 can both inhibit 
and activate beta-catenin signaling (Wu et al., 2000), 
and co-receptor class of Kremen protein facilitates 
DKK1, 2, and 4 binding to block Wnt signaling (Bafico 
et al., 2001).  
However, DKK3 neither bind to LRP5/6 nor does 
Kremen (Mao et al., 2003; Brott et al., 2001). 
The receptor for DKK3 is yet to be investigated and its 
Wnt/beta-catenin inhibitory function is still elusive 
(Veeck et al., 2012).  
However, Wnt modulating function of DKK3 are 
reported in several kinds of malignancies including 
glioma (Mizobuchi et al., 2008), breast cancer (Wang 
et al., 2008), prostate cancer (Abarzua et al., 2005 and 
Kawano et al., 2006) and lung cancer (Yue et al., 
2008).  
And because of its obvious tumor suppressor functio, 
DKK3 is regarded as tumor suppressor. 
Recently, intracellular function of DKK3 was noted. 
Cytoplasmic DKK3 may bind to beta TrCP, and 
facilitate beta-catenin degradation (Lee et al., 2009). 
 
 
DKK family is known as a negative regulator of Wnt signaling. There are three pathways in Wnt signaling, Wnt/beta-catenin pathway, 
planar cell polarity pathway and Wnt/Ca2+ cascade. Wnt/beta-catenin pathway is called canonical pathway and latter two are called non-
canonical pathway. In Wnt/beta-catenin pathway, cytoplasmic beta-catenin is ubiquitinated and degraded without Wnt ligand binding. 
When Wnt ligands bind to the receptor complex, Frizzled and Lrp5/6, cytoplasmic beta-catenin is stabilized and translocated into the 
nucleus, inducing TCF/LEF mediated transcription. DKK family members antagonize this pathway by binding Lrp5/6 and Kremen. Among 
DKK family member, DKK1, 2 and 4 can bind to LRP5/6, but DKK3 cannot. DKK2 can also activate beta-catenin accumulation. Binding of 
DKKs with LRP5/6 and Kremen complex resulted in endocytosis of Kremen. 
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In cancers, DKK3 mRNA expression is down-regulated 
by promoter methylation (see below), but there is a 
discrepancy between mRNA expression and protein 
expression in tissue samples, which may reflect tumor 
heterogeneity. 
Homology 
DKK3 homolog is conserved over species, in 
vertebrates including zebrafish, murine, rat, chicken, 
dog, cow, Rhesus monkey and chimpanzee and 
invertebrate, such as Dictyostelium, cnidarian, tunicate 
and ascidian. 
In vertebrates, DKK proteins consist from 4 members 
(i.e. DKK1, 2, 3 and 4). Although all these proteins 
possess two cysteine-rich domains, the homology 
among DKK1, 2 and 4 is 41-50%, whereas that 
between DKK3 and other members it is 37-40%. 
Mutations 
Note 
Neither germinal nor somatic mutation is reported. 5 
single nucleotide polymorphisms (SNP) are known 
(rs3206824, rs11022095, rs1472189, rs7396187, and 
rs2291599). Please refer to the link below. 
Implicated in 
Brain tumors (neuroblastoma, glioma 
and ganglioneuroma) 
Note 
DKK3 protein expression is down-regulated in brain 
tumors.  
In neuroblastoma, DKK3 mRNA expression is low. 
DKK3 functions as tumor suppressor, and its 
expression is negatively regulated via miR92, which is 
up-regulated by MYCN (De Brouwer et al., 2012; 
Haug et al., 2011).  
In ganglioneuroma, DKK3 expression is high (Koppen 
et al., 2008). 
In glioma and malignant glioma, DNA 
hypermethylation in DKK3 and consequent reduced 
expression of DKK3 protein are observed.  
Forced expression of DKK3 in glioma cell lines 
induces JUN phosphorylation-mediated apoptosis 
(Götze et al., 2010; Mizobuchi et al., 2008). 
Prognosis 
Low DKK3 expression in neuroblastoma correlates 
with poor prognosis. 
Oncogenesis 
DKK3 methylation status may indicate neuroblastic 
tumor maturation. 
Head and neck and oral cancers 
Note 
Some reports indicate that loss of DKK3 function may 
be involved in oral, and head and neck squamous cell 
carcinomas (SCC). Frequent LOH in DKK3 locus 
(11p15.2) is reported (Katase et al., 2008).  
DKK3 mRNA expression is decreased in oral SCC 
tissue sample and cell lines (Pannone et al., 2010).  
However, protein expression status is different. DKK3 
protein is dominantly expressed in oral SCC tissue 
sample and cell line (Katase et al., 2012).  
Moreover, DKK3 knockdown in oral SCC derived cells 
resulted in reduced cell migration and invasion (Katase 
et al., 2013).  
DKK3 expression increases from epithelial dysplasia, 
carcinoma in situ to invasive cancer, and is though to 
be independent with Wnt/beta-catenin pathway (Fujii et 
al., 2011). 
Prognosis 
LOH in DKK3 locus inversely correlates with lymph 
nodal metastasis and overall survival. DKK3 protein 
expression correlates with shorter disease free survival, 
metastasis free survival. 
Oncogenesis 
DKK3 is suggested to be involved in SCC 
carcinogenesis in head and neck, and oral region. 
However, its detailed function is yet to be investiga ed. 
Esophageal cancer 
Note 
DKK3 DNA is hypermethylated in esophageal cancer 
patient samples and cell lines (Liu et al., 2011; Maehata 
et al., 2008). However, one report indicates that DKK3 
protein is overexpressed (Zhang et al., 2010). 
Prognosis 
Methylation of DKK3 predicts risk of recurrence. 
DKK3 protein expression correlates with invasive 
depth, lymph nodal metastasis and advanced TNM 
stage. 
Oncogenesis 




In gastric adenocarcinoma cell lines, DKK3 mRNA 
expression is down-regulated (Yu et al., 2009; Maehata 
et al., 2008; Sato et al., 2007). However, in tissue 
samples, DKK3 protein expression was observed. 
DKK3 protein expression is also observed in tumor 
endothelium adjacent to cancer tissue (Mühlmann et 
al., 2010).  
In mice gastric scirrhous carcinoma model, 
intraperitoneal administration of adenovirus vector 
carrying DKK3 significantly decreases tumor 
dissemination and increased recruitment of killer T 
cells (Than et al., 2011). 
Prognosis 
Methylation of DKK3 is a prognostic predictor for 
shorter survival. DKK3 protein expression in cancer  
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cells is associated with pT-stage and UICC stage. 
DKK3 protein expression correlates with favorable 
prognosis. 
Oncogenesis 
Reduced DKK3 mRNA expression by CpG 
methylation is thought to be involved in gastric can er 
development, and might be a potential clinical target. 
Colorectal cancer 
Note 
In colorectal adenocarcinoma cell lines, DKK3 
expression is down-regulated both in mRNA and 
protein level. Forced overexpression of DKK3 mRNA 
results in G0/G1 cell cycle arrest, induction of 
apoptosis and reduced cell proliferation. Increased 
cytoplasmic beta-catenin is also noted (Yang et al., 
2012).  
In clinical tissue samples, DKK3 protein expression is 
decreased compared to corresponding normal tissues, 
and DKK3 expression correlates with invasion depth, 
TNM stage and dedifferentiation (Wang et al., 2012). 
DKK3 protein expression in tumor vessels is noted. 
Immunohistochemical analysis revealed that vessels 
in/adjacent to the cancer tissue shows DKK3 protein 
expression, whereas normal vessels do not. This 
implies pro-angiogenic function of DKK3 protein (Zitt 
et al., 2008; Untergasser et al., 2008). 
Oncogenesis 
DKK3 might be involved in carcinogenesis of 
colorectal cancer via Wnt/beta-catenin pathway. 
Liver tumors, hepatocellular carcinoma 
and hepatoblastoma 
Note 
In hepatocellular carcinoma (HCC) and cirrhosis-
related HCC tissue samples, DKK3 mRNA expression 
is low because of promoter hypermethylation (Yang et 
al., 2010; Ding et al., 2009).  
However, in HCC and hepatoblastomas tissue sample, 
DKK3 protein expression is up-regulated (Pei et al.,
2009). 
Prognosis 
Hypermethylation of DKK3 may correlate to shorter 
progression free survival in cirrhosis-related HCC. 
Hypermethylation is more frequent in high-grade 
tumor. 
Oncogenesis 
DKK3 may be involved in tumorigenesis of HCC and 
associated with dedifferentiated nature. 
Pancreatic cancer 
Note 
DKK3 expression is low in pancreatic cancer cell lines 
(MIA PaCa-2 and AsPC-1), due to DNA methylation. 
DKK3 expression in transfection of expressing 
plasmids decreased cell proliferation and beta-catenin 
expression (Gu et al., 2011).  
However, another report indicates that DKK3 
expression is overexpressed in PANC-1 cell line 
(derived from human pancreatic ductal carcinoma), and 
that its down-regulation results in reduction in cellular 
proliferation (Zenzmaier et al., 2012). 
DKK3 protein expression in tissue samples revealed 
that DKK3 protein expression is observed both in 
cancer cells and tumor endothelium (Fong et al., 2009). 
Prognosis 
DKK3 expressing endothelium is sensitive to 
anticancer drug. Low DKK3 protein expression in 
tumor endothelium correlates with worse clinical 
outcome. 
Oncogenesis 
DKK3 may be involved in carcinogenesis in pancreatic 
carcinoma via Wnt/beta-catenin signaling. 
Hematopoietic neoplasm and leukemias 
Note 
The possible function of DKK3 as immune modulator 
and involvement in hematopoietic neoplasms are 
reported. As for chronic lymphatic leukemia (CLL), 
CLL-derived cell line demonstrated DKK3 methylation 
ranging 23-37%. DKK3 methylation is also observed in 
CLL patients, ranging 18.7-61% (Moskalev et al., 
2012). 
A small population of acute myeloid leukemia (AML) 
patient shows DKK3 methylation (Griffiths et al., 
2010; Valencia et al., 2009). 
DKK3 methylation is also reported in acute lymphatic 
leukemia (ALL) derived cell lines and patients 
(Roman-Gomez et al., 2004). 
Recombinant DKK3 may alter CD14+ monocyte into 
novel phenotype, which demonstrates dendritic cell like 
appearance and IL-4, GM-CSF. Administration of 
recombinant DKK3 results in tumor regression with 
CD11c+, CD8+ T-cell infiltration (Watanabe et al., 
2009). 
Prognosis 
DKK3 methylation is a prognostic predictor of disea 
free survival in ALL. 
Cervical cancer 
Note 
In cervical squamous cell carcinoma (SCC) tissue 
samples and cell lines, DNA methylation of DKK3 is 
reported (Kang et al., 2012). Overexpression in cervi al 
SCC cell line results in reduction of cellular beta-
catenin level (Lee et al., 2009).  
DKK3 methylation is reported also in cervical 
adenocarcinoma (van der Meide et al., 2011). 
Prognosis 
DKK3 DNA methylation status may correlate with 
larger tumor size and shorter disease free survival. 
Oncogenesis 
DKK3 methylation and aberrant Wnt/beta-catenin 
signaling may be involved in cervical SCC. 
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Ovarian and endometrial cancers 
Note 
DKK3 mRNA expression is decreased in ovarian 
cancer tissue (You et al., 2011), and serum DKK3 
protein level is low in ovarian cancer patients compared 
to non-cancerous subject (Jiang et al., 2010). 
In endometrial cancer tissue samples, DKK3 mRNA 
expression is down-regulated, and overexpression in 
endometrial cancer cell lines results in reduced cell 
proliferation and beta-catenin mediated TCF activity 
(Dellinger et al., 2012). 
Prognosis 
Low serum DKK3 level correlate with high frequency 
of lymph nodal metastasis. Low DKK3 mRNA level 
correlates with high stage and high incidence of lymph 
nodal metastasis. 
Oncogenesis 
DKK3 may be involved in carcinogenesis of ovarian 
and endometrial cancer. 
Breast cancer 
Note 
DNA hypermethylation of DKK3 is reported both in 
breast cancer tissue samples and cell lines (Veeck t al., 
2008; Veeck et al., 2009; Fujikane et al., 2010).  
Forced expression in cancer cell lines results in 
induction of JNK-mediated apoptosis and reduction of 
anticancer drug resistance (Kawasaki et al., 2009).  
Another report demonstrated that knockdown of DKK3 
by shRNA transfection revealed the possible functio 
of DKK3 as modulator of Wnt/beta-catenin signaling 
modulator in breast cancer (Wang et al., 2008). 
Prognosis 
DKK3 DNA methylation status may be a prognostic 
factor for disease free survival and overall survival. 
Oncogenesis 
DKK3 may be involved in carcinogenesis of breast 
cancer, and may modulate Wnt/beta-catenin signaling. 
Renal and bladder cancers 
Note 
In renal cell carcinoma (RCC), DKK3 mRNA 
expression is down-regulated because of promoter CpG 
island methylation.  
Stable transfection of DKK3 in RCC cell lines does not
affect in Wnt/beta-catenin pathway, but induce 
apoptosis via JNK pathway (Ueno et al., 2011). 
Methylation of DKK3 is also observed in renal clear 
cell carcinoma (RCCC) (Kurose et al., 2004). 
SNP in DKK3 gene is reported in RCC (Hirata et al.,
2009). 
DKK3 methylation is observed in bladder cancer, and
forced expression in bladder cancer cell lines induces 
JNK mediated apoptosis (Urakami et al., 2006; Hirata 
et al., 2012; Jin et al., 2012). 
Prognosis 
rs1472189 SNP correlates with distant metastasis. 
Oncogenesis 
DKK3 methylation may be involved in carcinogenesis 
in RCC and bladder carcinoma. 
Prostate and testicular cancers 
Note 
In prostate cancer, mRNA and protein expression are 
down-regulated. DKK3 protein expression in prostate 
cancer decreases gradually in prostate carcinogenesis 
(Kawano et al., 2006; Zenzmaier et al., 2008).  
High DKK3 protein level is reported in seminal plasma 
of prostate cancer patients (Zenzmaier et al., 2011). 
Overexpression in prostate cancer cell line induces 
JNK-mediated apoptosis (Abarzua et al., 2005) and 
decreases lymph nodal metastasis in prostate cancer 
mice model (Edamura et al., 2007; Chen et al., 2009). 
In testicular cancer, DKK3 expression is down-
regulated, and forced expression in cancer cell lines 
induce JNK-mediated apoptosis (Tanimoto et al., 
2007). 
Prognosis 
DKK3 protein expression loss may correlate to tumor 
grade. Overexpression of DKK3 in prostate cancer 
model may ameliorate tumor progression. 
Oncogenesis 
DKK3 methylation may be involved in carcinogenesis 
in prostate and testicular cancers. 
Lung cancer and mesothelioma 
Note 
Reduced DKK3 mRNA level is firstly reported in 
human non-small cell lung cancer (NSCLC) tissue 
sample (Nozaki et al., 2001). Decreased expression of 
DKK3 mRNA is due to DNA methylation, and DKK3 
may regulate cancer cell growth via Wnt/beta-catenin 
pathway (Yue et al., 2008). DKK3 methylation is 
observed also in precarcinomatous lesion, atypical 
adenomatous hyperplasia (Licchesi et al., 2008).  
In mesothelioma cell line, DKK3 expression is down-
regulated, and overexpression of DKK3 induces JNK-
mediated apoptosis (Kashiwakura et al., 2008). 
Oncogenesis 
DKK3 may be involved in NSCLC via Wnt/beta-
catenin signaling regulation. 
Skin cancer and malignant melanoma 
Note 
DKK3 protein expression is down-regulated in skin 
cancers (Du et al., 2011). In malignant melanoma tissue 
sample and cell lines, DKK3 mRNA expression is 
strongly reduced. Stable expression of DKK3 in 
malignant melanoma reduces cellular migration 
(Kuphal et al., 2006). 
Oncogenesis 
DKK3 may function as a tumor suppressor in skin 
tumors and malignant melanoma. 
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Osteosarcoma 
Note 
Osteosarcoma-derived cell line, Saos2 shows decreased 
expression of DKK3, which may modulate Wnt/beta-
catenin signaling (Hoang et al., 2004). 
Oncogenesis 




DKK3 level in the cerebrospinal fluid in Alzheimer's 
disease patients is higher than plasma DKK3 level 
(Zenzmaier et al., 2009). 
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